Your browser doesn't support javascript.
loading
The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.
Biondetti, Emma; Santin, Mathieu D; Valabrègue, Romain; Mangone, Graziella; Gaurav, Rahul; Pyatigorskaya, Nadya; Hutchison, Matthew; Yahia-Cherif, Lydia; Villain, Nicolas; Habert, Marie-Odile; Arnulf, Isabelle; Leu-Semenescu, Smaranda; Dodet, Pauline; Vila, Miquel; Corvol, Jean-Christophe; Vidailhet, Marie; Lehéricy, Stéphane.
Afiliação
  • Biondetti E; Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.
  • Santin MD; ICM, Centre de NeuroImagerie de Recherche - CENIR, 75013 Paris, France.
  • Valabrègue R; ICM, Team "Movement Investigations and Therapeutics" (MOV'IT), 75013 Paris, France.
  • Mangone G; Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.
  • Gaurav R; ICM, Centre de NeuroImagerie de Recherche - CENIR, 75013 Paris, France.
  • Pyatigorskaya N; Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.
  • Hutchison M; ICM, Centre de NeuroImagerie de Recherche - CENIR, 75013 Paris, France.
  • Yahia-Cherif L; Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.
  • Villain N; Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Neurology, Centre d'Investigation Clinique Neurosciences, 75013 Paris, France.
  • Habert MO; Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Neurology, 75013 Paris, France.
  • Arnulf I; Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.
  • Leu-Semenescu S; ICM, Centre de NeuroImagerie de Recherche - CENIR, 75013 Paris, France.
  • Dodet P; ICM, Team "Movement Investigations and Therapeutics" (MOV'IT), 75013 Paris, France.
  • Vila M; Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.
  • Corvol JC; ICM, Team "Movement Investigations and Therapeutics" (MOV'IT), 75013 Paris, France.
  • Vidailhet M; Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Neuroradiology, 75013 Paris, France.
  • Lehéricy S; Biogen Inc., Cambridge, MA 02142, USA.
Brain ; 144(10): 3114-3125, 2021 11 29.
Article em En | MEDLINE | ID: mdl-33978742
ABSTRACT
In Parkinson's disease, there is a progressive reduction in striatal dopaminergic function, and loss of neuromelanin-containing dopaminergic neurons and increased iron deposition in the substantia nigra. We tested the hypothesis of a relationship between impairment of the dopaminergic system and changes in the iron metabolism. Based on imaging data of patients with prodromal and early clinical Parkinson's disease, we assessed the spatiotemporal ordering of such changes and relationships in the sensorimotor, associative and limbic territories of the nigrostriatal system. Patients with Parkinson's disease (disease duration < 4 years) or idiopathic REM sleep behaviour disorder (a prodromal form of Parkinson's disease) and healthy controls underwent longitudinal examination (baseline and 2-year follow-up). Neuromelanin and iron sensitive MRI and dopamine transporter single-photon emission tomography were performed to assess nigrostriatal levels of neuromelanin, iron, and dopamine. For all three functional territories of the nigrostriatal system, in the clinically most and least affected hemispheres separately, the following was performed cross-sectional and longitudinal intergroup difference analysis of striatal dopamine and iron, and nigral neuromelanin and iron; in Parkinson's disease patients, exponential fitting analysis to assess the duration of the prodromal phase and the temporal ordering of changes in dopamine, neuromelanin or iron relative to controls; and voxel-wise correlation analysis to investigate concomitant spatial changes in dopamine-iron, dopamine-neuromelanin and neuromelanin-iron in the substantia nigra pars compacta. The temporal ordering of dopaminergic changes followed the known spatial pattern of progression involving first the sensorimotor, then the associative and limbic striatal and nigral regions. Striatal dopaminergic denervation occurred first followed by abnormal iron metabolism and finally neuromelanin changes in the substantia nigra pars compacta, which followed the same spatial and temporal gradient observed in the striatum but shifted in time. In conclusion, dopaminergic striatal dysfunction and cell loss in the substantia nigra pars compacta are interrelated with increased nigral iron content.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Substância Negra / Dopamina / Corpo Estriado / Ferro / Melaninas Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Brain Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Substância Negra / Dopamina / Corpo Estriado / Ferro / Melaninas Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Brain Ano de publicação: 2021 Tipo de documento: Article